Salute e Benessere

AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development…

LONDON and PHOENIX, July17, 2023(GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and EmeritusDX, a rapidly growing cancer diagnostics and information company, today announced the execution of an agreement wherein both companies will jointly manage scientific operations and R&D for AccuStem's product portfolio. Initial plans as part of the collaboration will be to immediately focus...
Nasdaq GlobeNewswire
17/07/2023

Eleven Therapeutics Announces Research Collaboration with Novo Nordisk to…

Uli Stilz, Head of Novo Nordisk's Bio Innovation Hub in Boston, stated, "Our research collaboration with Eleven Therapeutics builds on Novo Nordisk's commitment to advancing precision medicine and opens up the opportunity to learn from one another as we explore novel cell-specific targeting strategies. With the combination of our joint team's expertise and using Eleven's DELiveri™ platform, we can potentially unlock transformative treatments for people living with cardiometabolic…
PR Newswire
17/07/2023

Orion Group Half-Year Financial Report 1–6/2023

ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2023 17 JULY 2023 at 12:00 EEST Orion Group Half-YearFinancial Report 1–6/2023 This is a summary or Orion's Half-Year Financial Report 1–6/2022. The complete report is attached to this stock exchange release and is available athttps://www.orion.fi/en/investors/reports-and-presentations/Net sales totalled EUR 567.5 (1–6/2022: 554.3) millionOperating profit was EUR 102.0 (153.4) millionProfit before taxes...
Nasdaq GlobeNewswire
17/07/2023

Repeat: Virbac reassesses its 2023 growth and Adjusted EBIT1 forecasts

Several elements are currently impacting our business and leading us today to revise our forecasts for the 2023 financial year. As a reminder, at constant rates and scope, our initial forecast for revenue growth was within a range of between 4% and 6% while our initial forecast for ratio of Adjusted EBIT 1was within a range of between 13% and 14%. We now expect revenue growth at constant rates and scope within a range of between 0% and 4%. The ratio of Adjusted EBIT 1should now...
Nasdaq GlobeNewswire
17/07/2023

COMPASS Pathways announces publication of positive data from treatment-resistant…

Results of COMPASS Pathways' open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 LONDON, July17, 2023(GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that positive data from an open-label phase 2 clinical trial of...
Nasdaq GlobeNewswire
17/07/2023

Orion Corporation's financial reporting and Annual General Meeting in 2024

ORION CORPORATIONSTOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 17 JULY 2023 at 11.00 EEST Orion Corporation's financial reporting and Annual General Meeting in 2024 Orion Corporation will publish its Financial Statement Release 2023 on Tuesday, 13 February 2024. The publication dates of the Interim Reports and the Half-Year Financial Report in 2024 are as follows:Interim Report January-March 2024 Half-Year Financial Report January-June 2024 Interim Report...
Nasdaq GlobeNewswire
17/07/2023

EXO Biologics Pioneers with EVENEW Clinical Trial in Broncho Pulmonary Dysplasia

First MSC-derived Extracellular Vesicles interventional study approved by the European Medicines Agency.Liège, Belgium 17 July 2023 – EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using Extracellular Vesicles (EVs) to treat rare diseases with high unmet medical needs, received approval from the European Medicines Agency (EMA) for the EVENEW study, enabling site activation in Europe. EVENEW is an adaptive, seamless Phase 1/2 trial assessing the...
Nasdaq GlobeNewswire
17/07/2023

Plastic Injection Molding Machine Market worth $11.6 billion by 2028 - Exclusive…

160 – Tables75 – Figures270 – Pages 160 – Tables 75 – Figures 270 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72063702 201-500 tons force is projected to register the highest CAGR, in terms of value, of the global plastic injection molding machine during the forecast period. The clamping force of 201–500 ton-force is majorly used in medium-sized plastic injection molding machines. Machine types such as hydraulic, all-electric, and...
PR Newswire
17/07/2023

Precedential US Federal Court Decision Hands SNIPR Biome a win in patent appeal…

SNIPR's successful appeal was based on the argument that all of SNIPR's patents have been filed under the America Invents Act (AIA), in which interferences were removed as a feature of the statute. The AIA was a systematic change to US patent law that moved from a first-to-invent standard to a first-to-file system, in line with Europe and other parts of the world. SNIPR's successful appeal was based on the argument that all of SNIPR's patents have been filed under the America Invents Act…
PR Newswire
17/07/2023

IDTechEx Discusses Applications of Antimicrobial Technology in Addressing…

While antimicrobial technologies have been shown to be extremely efficient in laboratory settings, these often do not match real-life conditions. Field tests and clinical trials within hospitals are required to understand if antimicrobial technologies can truly lower the rate of HAIs. While antimicrobial technologies have been shown to be extremely efficient in laboratory settings, these often do not match real-life conditions. Field tests and clinical trials within hospitals are required to...
PR Newswire
17/07/2023

OrganOx Raises £25 Million in Growth Round Led by Lauxera Capital Partners

metra ® , a fully automated normothermic machine perfusion (NMP) device for liver transplantation, today announces that it has raised £25 million in a growth round led by Lauxera Capital Partners (“Lauxera”) with support from existing investors. The proceeds from the fundraise will enable OrganOx to significantly expand its commercial footprint across strategically key areas of the business. This includes expanding the customer-facing team in the United States due to high interest and...
Nasdaq GlobeNewswire
17/07/2023

Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules…

Cumulus Oncology and leadXpro Announce Collaboration toDevelop Small Molecules against Novel Cancer-Focused GPCR Targets Resulting IP will be licensed into a newly created Cumulus company Edinburgh, Scotland, and Villigen , Switzerland 17thJuly 2023. Cumulus Oncology (“Cumulus”) and leadXpro AG (“leadXpro”) today announce they have signed a research collaboration focused on the discovery and development of small molecules targeting an undisclosed...
Nasdaq GlobeNewswire
17/07/2023

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of…

Acromegaly is a rare and severe chronic disease caused by a benign pituitary tumor causing excess levels of growth hormone (GH), leading to increased levels of insulin-like growth factor-1 (IGF-1). The disease causes significant morbidity, physical changes, burdensome symptoms, and diminished quality of life of patients.1-3 First-line medical treatment of acromegaly is represented by first-generation injectable somatostatin receptor ligands (SRL), octreotide and lanreotide. Acromegaly is a…
PR Newswire
17/07/2023

LUXASIA bags double hat-trick with third win at Deloitte's Best Managed…

Emerging from Deloitte's strict assessment, the judging panel commended LUXASIA for its clear and strategic market penetration plan for future growth, focus on technology to improve operational efficiency and customer experience, as well as its commitment to enhancing talent acquisition, human capital management, and brand visibility. Since their last win, the Group has expanded its brand portfolio through major partnerships with the likes of Dolce & Gabbana, Huda Beauty, Laura Mercier…
PR Newswire
17/07/2023

MGI Empowers Life Sciences Industry with Revolutionary What If Campaign at…

Under "What If?", MGI sets out to redirect the industry dialogue from competition and comparison of platform specifications to customer-centered solutions by prompting scientists, researchers and decision-makers to tap into the possibilities of their most pressing genomics needs and desires being met. Under "What If?", MGI sets out to redirect the industry dialogue from competition and comparison of platform specifications to customer-centered solutions by prompting…
PR Newswire
17/07/2023

Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting…

Vivoryon Therapeutics N.V.Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer's Disease Small molecule varoglutamstat, with potential for meaningful safety and ease of use advantages over antibody-based therapies, continues to show encouraging safety data at therapeutic dose of 600 mg twice daily , a dose demonstrated to result in nearly 90% target occupancyVIVIAD data presented at...
Nasdaq GlobeNewswire
16/07/2023

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC…

Regulated InformationLeuven, BELGIUM, Boston, MA, US – July 14 , 2023 – 7 .00PM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on July 13, 2023,...
Nasdaq GlobeNewswire
14/07/2023

Sobi KOL investor event: the journey for Vonjo®

STOCKHOLM, July 14, 2023 Following the completion of Sobi's acquisition of CTI Biopharma, Sobi's management will host a virtual KOL event. STOCKHOLM , July 14, 2023 Following the completion of Sobi's acquisition of CTI Biopharma, Sobi's management will host a virtual KOL event. Sarah Buckley, VP and Head of Clinical Affairs at CTI Biopharma, and Key Opinion Leader, DrJohn Mascarenhas, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, will discuss the clinical...
PR Newswire
14/07/2023

AI in Pathology Market worth $49 million | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=86647266 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=86647266 Browse in-depth TOC on "AI in Pathology Market" 248 - Tables 48 - Figures 265 - Pages AI in Pathology Market Scope: Software segment accounted for the largest share of the AI in pathology market, By component. Based on component, the software segment accounted for the...
PR Newswire
14/07/2023

Gene Editing Market worth $10.6 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000 Browse in-depth TOC on "Gene Editing Market" 194 - Tables 48 - Figures 216 - Pages Gene Editing Market Scope: The reagents and consumables segment accounted for the largest share of the gene editing market in 2022 Based on product & service, the gene editing...
PR Newswire
14/07/2023

Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to…

Versanis' lead asset is bimagrumab, a first-in-class, fully human monoclonal antibody to activin type II receptors that blocks binding of ligands including myostatin, activins, and GDF11. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone or in combination with semaglutide in adults living with overweight or obesity. Combining incretins with bimagrumab has the potential to improve the quality and durability of weight loss, with the goal of achieving better outcomes for…
PR Newswire
14/07/2023

Clario Bolsters Executive Leadership Team with New Chief Financial Officer…

Jason Knoblauch will join Clario as Chief Financial Officer, effective August 7, 2023. Jason Knoblauchwill join Clario as Chief Financial Officer, effectiveAugust 7, 2023. Jason joins Clario from Curia, a global contract research, development, and manufacturing organization, where he served as Chief Financial Officer. Prior to his tenure at Curia, Jason held various financial leadership roles at PPD, including serving as interim CFO in 2018, and was a director in PwC's Transaction...
PR Newswire
14/07/2023

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for…

For the disease's bacterial component, AB-101a is clearing all AD infections and is demonstrating control of the bacterial microbiome on the AD skin to manage flares driven by bacteria in mild, moderate, and severe levels of the disease. For AD's immune system component, AB-101a is reducing itch and showing improvement in the Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) AD scores. The results were presented in a poster at The Society for Pediatric Dermatology…
PR Newswire
14/07/2023

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to…

BBS-Bioactive Bone Substitutes Plc, Company announcement, 14 July 2023 14:00 p.m. BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd BBS-Bioactive Bone Substitutes Plc (“BBS” or the "Company") has received a request by Riverfort Global Opportunities PCC Ltd to convert a proportion of EUR 50,000 of the convertible notes into Company shares at a conversion price of EUR 0...
Nasdaq GlobeNewswire
14/07/2023
Altri  Comunicati